TY - JOUR
T1 - Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity
AU - Tsutsumi, Kuniaki
AU - Kaname, Takanori
AU - Shiraishi, Haruka
AU - Kawashiri, Takehiro
AU - Egashira, Nobuaki
N1 - Funding Information:
Part of this study was supported by JSPS KAKENHI , grant numbers 25460335 and 16K19184 . We appreciate the technical support received from the Research Support Center, Graduate School of Medical Sciences, Kyushu University.
Publisher Copyright:
© 2016 The Authors
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy.
AB - Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy.
UR - http://www.scopus.com/inward/record.url?scp=84973861918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973861918&partnerID=8YFLogxK
U2 - 10.1016/j.jphs.2016.04.019
DO - 10.1016/j.jphs.2016.04.019
M3 - Article
C2 - 27262900
AN - SCOPUS:84973861918
SN - 1347-8613
VL - 131
SP - 146
EP - 149
JO - Journal of Pharmacological Sciences
JF - Journal of Pharmacological Sciences
IS - 2
ER -